These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38015548)

  • 1. Mutational and expressional association of the PIK3CA gene with the risk of breast cancer in the Pakistani population.
    Abbasi SA; Khan R; Ahmed MN; Hussain K; Riaz A; Mansoor Q; Qayyum M; Mehmood Baig R
    Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):1-8. PubMed ID: 38015548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
    Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
    Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
    Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
    Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
    López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
    Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients.
    Tong L; Yang XX; Liu MF; Yao GY; Dong JY; Ye CS; Li M
    Asian Pac J Cancer Prev; 2012; 13(11):5599-603. PubMed ID: 23317280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.
    Lasota J; Felisiak-Golabek A; Wasag B; Kowalik A; Zięba S; Chłopek M; Wang ZF; Coates T; Kopczynski J; Gozdz S; Sarlomo-Rikala M; Miettinen M
    Mod Pathol; 2016 Mar; 29(3):275-82. PubMed ID: 26796526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel PIK3CA hotspot mutation in Isfahanian breast cancer patients.
    Gharbi S; Faghihi M; Tavassoli M
    Cancer Invest; 2011 May; 29(4):313-7. PubMed ID: 21345071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.
    Tharin Z; Richard C; Derangère V; Ilie A; Arnould L; Ghiringhelli F; Boidot R; Ladoire S
    Sci Rep; 2023 Mar; 13(1):4467. PubMed ID: 36934165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
    Dumont AG; Dumont SN; Trent JC
    Chin J Cancer; 2012 Jul; 31(7):327-34. PubMed ID: 22640628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.
    Sivakumar S; Jin DX; Rathod R; Ross J; Cantley LC; Scaltriti M; Chen JW; Hutchinson KE; Wilson TR; Sokol ES; Vasan N
    Clin Cancer Res; 2023 Mar; 29(6):1125-1136. PubMed ID: 36595567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
    Cizkova M; Cizeron-Clairac G; Vacher S; Susini A; Andrieu C; Lidereau R; Bièche I
    PLoS One; 2010 Dec; 5(12):e15647. PubMed ID: 21209903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.